Is Ixabepilone available in China?

Ixabepilone is a semi-synthetic microtubule stabilizer anti-tumor drug, mainly used for the treatment of advanced or metastatic breast cancer, especially for patients after failure of other chemotherapy regimens. Its mechanism of action is to inhibit tumor growth by stabilizing the microtubule structure and preventing cancer cell division and proliferation. Since being approved by the U.S. FDA in October 2007, ixabepilone has been widely used in the field of tumor treatment in Europe, the United States and some Asian countries.

However, ixabepilone has not yet been approved for marketing in China. This means that domestic patients cannot obtain the drug through regular hospitals or medical insurance channels, and it is not included in the Class B or Class C medical insurance reimbursement system. At the same time, no generic version of the drug has yet been launched in the country, which limits the accessibility of the drug in the country. The specifications listed overseas are mainly 15mg and 45mg, with prices ranging from US$2,000 to US$6,000 respectively. The price is relatively high, and use under the guidance of a professional doctor is required.

Since it has not yet been marketed in China, if patients want to use ixabepilone, they usually need to obtain it through overseas medical treatment or international drug introduction channels, which poses a certain threshold for ordinary patients. Before use, doctors need to comprehensively evaluate the patient's hematological indicators, liver and kidney function, and previous chemotherapy history to ensure the safety and tolerability of the drug.

Although the domestic launch has not yet been achieved, as the approval process for international anti-cancer drugs entering China is accelerated, ixabepilone is expected to enter the domestic market in the future. By then, domestic breast cancer patients will have more chemotherapy options, especially for patients with drug-resistant or recurrent advanced breast cancer, ixabepilone will become an important treatment option. At the same time, domestic generic drug research and development may also drive down drug prices and improve patient accessibility.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html